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Vascular and cardiac valve calcification is associated with cardiovascular mortality in the general population. Increasing
clinical and experimental evidence suggests that inflammation accelerates the progression of calcification, which has
molecules in common with bone metabolism. For example, osteopontin (OPN), osteoprotegerin (OPG), receptor
activator of the nuclear factor κB ligand (RANKL), and alkaline phosphatase (ALP) are proposed to play central roles in
the calcification or demineralization of atherosclerotic lesions and the calcification of cardiac valves. Abnormalities in
the balance of these proteins may lead to perturbations in vascular/valve calcification. “How to prevent calcification” is
a common task based on conventional data; however, several pathological findings indicate that heavily calcified
plaques are stable, which may not lead to coronary events. Vulnerable plaques tend to be either noncalcified or only
mildly or moderately calcified. “How to treat calcification,” which depends on the details of the specific patient, thus
remains a difficult challenge. In addition to the detection of calcification, characterization as well as quantification of it
is necessary for optimal treatment of this pathology in the future.
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The saying “a man is as old as his arteries” (a person
grows old with their blood vessels), which William Osler
quoted to describe the association between blood vessels
and anti-aging in 1898 [1], remains relevant for many
researchers and clinicians who are studying the central
concepts of anti-aging. We have realized the importance
of these words with the arrival of gluttony and the aging
of our society over the past 100 years. For many decades,
vascular and cardiac valve calcification has been regarded
as consequences of aging. Studies now confirm that vascu-
lar and valvular calcification is an actively regulated
process and shares many features with bone development
and metabolism. Here, we focus on the molecular
mechanism underlying the calcification of the aorta and
cardiac valves and propose an answer to the question of
“how to treat calcification”.* Correspondence: nakagami@gts.med.osaka-u.ac.jp
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Aortic calcification is an aging marker during the pro-
gression of atherosclerosis. Many studies have reported
that aortic calcification and cardiovascular events are
highly related in the elderly. This has been demonstrated
with the development of recent diagnostic imaging sys-
tems. Rodondi et al. prospectively investigated the prog-
noses of patients aged more than 65 years with vascular
calcification for 13 years to determine whether aortic
calcification is a risk factor of cardiovascular disease [2].
Patients with aortic calcification were more likely to die
of any cause (47 vs. 27 %, P < 0.001) and cardiovascular-
specific causes (18 vs. 11 %, P < 0.001) during follow-up
than those without aortic calcification. In analyses
adjusted for age and cardiovascular risk factors, aortic
calcification was associated with an increased rate of all-
cause mortality (hazard ratio (HR), 1.37; 95 % confidence
interval (CI), 1.15–1.64) [2]. Okuno et al. followed 515
hemodialysis patients, of whom 291 patients (56.5 %)
had abdominal aortic calcification (AAC) [3]. During a
mean follow-up of 51 months, there were 103 all-cause
deaths, of which 41 were from cardiovascular diseases.
Of patients with and without AAC, 27.8 and 9.8 % died,
respectively (11.6 and 3.1 % from cardiovascularicle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made.
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Cox proportional hazards analysis, the presence of AAC
was significantly associated with increased all-cause
mortality (HR, 2.07; 95 % CI, 1.21–3.56) and increased
cardiovascular mortality (HR, 2.39; 95 % CI, 1.01–5.66)
after adjustment for age, hemodialysis duration, diabetes,
serum albumin level, and C-reactive protein level. These
epidemiologic studies suggest that aortic calcification
may be a risk factor as well as a complication.
Vascular calcification and osteoporosis are common
age-related processes and are associated with adverse
clinical outcomes, including ischemic cardiac events,
claudication, and mortality. Vascular calcification was
previously considered passive and degenerative, but it is
now recognized as a pathobiological process sharing
many features with embryonic bone formation. Import-
antly, several bone matrix proteins are expressed in
calcified arteries, which indicate that the cellular and
molecular mechanisms of arterial calcification are
similar to those of bone metabolism. Bostrom et al.
demonstrated the expression of osteogenic differenti-
ation factor bone morphogenetic protein-2 (BMP-2) in
calcified human plaques and blood vessel tissue consti-
tutive cells, such as endothelial cells (ECs), vascular
smooth muscle cells (VSMCs), and macrophages, in
vascular calcification. Furthermore, it was shown thatFig. 1 Scheme of vascular calcification through the RANK/RANKL/OPG axis
cells (VSMCs), and RANKL is primarily expressed in VSMCs. RANKL directly s
and indirectly promotes osteogenesis via BMP2, which is part of the TGF-β
in VSMCs leads to synthesis of bone proteins and matrix calcification withinVSMCs could be differentiated into osteoblast-like cells
by stimulation with BMP-2 [4]. Both bone metabolic
disorder and vascular calcification are degenerative dis-
eases that are common in the elderly population, and they
are frequently observed in the same individuals. The
constancy of mineral metabolism is maintained by the
active balance of osteoblasts and osteoclasts in bone
tissue; however, the contribution of osteoclast-like cells to
aortic calcification is not yet well understood. Thus, the
mineralization processes in bone metabolism and those in
vascular calcification may be somewhat different.
The RANKL system in vascular and valve calcification
To address the unexplored mechanisms for this
phenomenon, we focused on the receptor activator of
nuclear factor κB (RANK), the RANK ligand (RANKL),
and osteoprotegerin (OPG) from the tumor necrosis
factor (TNF)-related family, which is associated with this
mechanism. RANKL is highly expressed by T cells in
lymphoid tissues and osteoblast/stromal cells in trabecu-
lar bone, particularly in areas undergoing active bone
remodeling or inflammatory osteolysis [5]. In the bone,
RANKL binds as a homotrimer to RANK on the surface
of monocyte/macrophage lineage cells, and RANKL
expression by osteoblasts/stromal cells is essential, to-
gether with permissive macrophage colony-stimulating. In vascular cells, RANK is expressed in both ECs and smooth muscle
timulates osteogenic differentiation of VSMCs via a decrease in MGP
superfamily, from ECs. Promoting osteogenic differentiation by RANKL
the arterial vessel
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osteoclasts from monocytic precursors under normal or
pathological conditions [5]. RANKL activities are blocked
by OPG, which functions as a decoy receptor to prevent
RANKL/RANK interactions and inhibits osteoclast forma-
tion. Interestingly, we demonstrated that the expression of
RANKL/RANK/OPG was upregulated in calcified arteries
and that RANKL accelerated differentiation of human
smooth muscle cells into osteoblast-like cells (Fig. 1). In a
human study, serum OPG levels were positively associated
with vascular calcification [6]. The diverse actions of
RANKL in the bone and the aorta may be the clues to
understanding mineralization during aortic calcification.
Aortic valve calcification and stenosis are major
medical problems facing an aging society. Calcification
of the aortic valve gets increasingly common and occurs
in conjunction with high mortality in the setting of
advanced age, congestive heart failure, and end-stage
renal disease, in which mechanical stress interacts with
metabolic and inflammatory disturbances. The identifi-
cation of osteoblast-like and osteoclast-like cells in
human tissue has led to a major paradigm shift in this
field. Although valve calcification was considered a
passive, degenerative, and untreatable disorder of “wear
and tear” unrelated to atherosclerosis, it is now recognizedFig. 2 Potential origin of cells that contribute to valve calcification and fibros
aortic valve. In interstitial cells, activated myofibroblasts are likely to arise from
undergo endothelial to mesenchymal transformation (EMT). RANKL increased
transcription factor runx2 in cultured human aortic valve myofibroblasts. OPGas a disease that is regulated similarly to atherosclerotic
calcification, which is promoted by systemic and local in-
flammatory milieu, characteristic of metabolic syndrome,
and type 2 diabetes. Ectopic mineralization of the aortic
valve involves several immunological reactions. Accumu-
lating evidence suggests that fibrocalcific remodeling of
the aortic valve is associated with activation of the NF-κB
pathway and that the expression of TNF-α and IL-6 are
increased in mineralized human aortic valves. These acti-
vators of the canonical NF-κB pathway promote an osteo-
genic process, as well as the mineralization of valve
interstitial cells (VICs), the main cellular component of
the aortic valve.
The RANKL/OPG axis may also regulate aortic valve
calcification. Bucay et al. reported that OPG-deficient
mice developed osteoporosis and valve calcification [7].
Kaden et al. showed that RANKL was present in human
stenotic aortic valves, but not in normal valves. Con-
versely, OPG expression was higher in normal valves
than in stenotic valves [8]. OPG-positive cells were
specifically decreased in areas of focal calcification.
Moreover, RANKL increased matrix calcification and
ALP activity and facilitated the osteoblast transcription
factor runx2 in cultured human aortic valve myofibro-
blasts (Fig. 2). In contrast, Weiss et al. demonstratedis. Valve interstitial cells (VICs) are the main cellular component of the
either quiescent VICs or a subpopulation of endothelial cells that
the matrix calcification, ALP activity, and activation of the osteoblast
prevents the interaction of RANKL with its receptor, RANK
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ApoB-100 mice fed a high fat diet, the administration of
OPG reduced valve calcification through the inhibition
of osteogenic transformation but did not prevent valve
fibrosis or lipid deposition, suggesting a specific effect of
OPG on calcification [9]. These observations suggest
that RANKL/OPG may regulate valve calcification both
directly and indirectly through regulation of the inflam-
matory response.
Therapeutic strategy for calcification
Vascular and valve calcification is an important diagnos-
tic and therapeutic target for the diagnosis and treat-
ment in an aging society. Many studies have reported
that vascular and valve calcification is highly associated
with mortality. Coronary artery calcium (CAC) has a
strong predictive value for incident cardiovascular
disease (CVD) events. The Agatston score, the standard
CAC score, is weighted upward for greater calcium
density. Criqui et al. conducted a multicenter, prospect-
ive observational Multi-Ethnic Study of Atherosclerosis
(MESA) study at six US field centers with 3398 men and
women aged 45 to 84 years [10]. During a median of
7.6 years of follow-up, CAC volume scores showed an
independent association with incident coronary heartFig. 3 Scheme of plaque calcification. Natural plaque progression involves
pools. Micro-calcifications are also commonly found within an overlying fib
fragments during therapy or atheroma progression, vessel wall stresses madisease (CHD), with a HR of 1.81 (95 % CI, 1.47–2.23)
per standard deviation (SD = 1.6) increase and an abso-
lute risk increase of 6.1 per 1000 person-years, and with
CVD, with HR of 1.68 (95 % CI, 1.42–1.98) per SD
increase and an absolute risk increase of 7.9 per 1000
person-years. As it progresses, valve calcification can
lead to more severe stenosis or regurgitation. Therefore,
it is a prognostic factor for cardiovascular mortality.
Because the development of calcification should be
prevented, several therapeutic drugs to suppress calcified
process have recently been described. Allison et al.
examined the relationship between estrogen therapy and
coronary artery calcium in a randomized clinical trial
[11]. They performed computed tomography of the heart
in 1064 postmenopausal women who were 50 to 79 years
of age at randomization and had undergone hysterec-
tomy. Coronary artery calcium (or Agatston) scores were
measured to evaluate calcification. After a mean of
7.4 years of treatment and an additional 1.3 years to be
performed (8.7 years after randomization), the mean
coronary artery calcium score was lower among women
receiving estrogen than among those receiving placebo
(83.1 vs. 123.1, P = 0.02 by rank test).
As described above, these observations suggest that
RANKL signaling may play a permissive role in thelipid-pool expansion coupled with micro-calcifications within lipid
rous cap. If these micro-calcifications coalesce into speckles and
y decrease significantly, contributing to plaque stability
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vascular and valve calcification has strong relationships
with immunity, and both innate and adaptive immunity
play a role in the development of calcification. As
discussed above, estrogen therapy may have anti-calcific
effects. In addition, denosumab, an anti-RANKL mono-
clonal antibody that is also used for the treatment of
osteoporosis, may also exert anti-calcific effects. How-
ever, because these therapies have complex biological ac-
tions possibly causing side effects, their uses in the
prevention of calcification is limited.
We have discussed “how to prevent calcification,” but
“how to treat preexisting calcification” remains unclear.
We hypothesized that calcification volume itself is re-
sponsible to the increased incidence of CVD events.
This hypothesis is supported by the observation that
CAC volume was positively and independently associ-
ated with CHD and CVD risk. Conversely, recent data
suggest that increased plaque calcium density may be pro-
tective against CVD. Criqui et al. also reported that CAC
density scores showed an independent inverse association
with CHD, with an HR of 0.73 (95 % CI, 0.58–0.91) per
SD (SD = 0.7) increase and an absolute risk decrease of
2.0 per 1000 person-years, as well as CVD, with an
HR of 0.71 (95 % CI, 0.60–0.85) per SD increase and
an absolute risk decrease 3.4 per 1000 person years
[10]. Moreover, Puri et al. reported the contribution
of micro-calcification to plaque progression, as shown
in Fig. 3. The micro-calcification is commonly ob-
served within an overlying fibrous cap and tends to
increase the risk of plaque rupture [12].
At any level of CAC volume, CAC density was in-
versely and significantly associated with CHD and CVD
risk [10]. The role of CAC density should be consid-
ered when evaluating current CAC scoring systems.
Recently, Hutcheson et al. demonstrated, using three-
dimensional collagen hydrogels and high-resolution
microscopic and spectroscopic analyses, that calcific
mineral formation and maturation results from a
series of events involving the aggregation of calcifying
extracellular vesicles and the formation of micro-
calcifications and ultimately large calcification areas
[13]. It is important to evaluate the treatment adapta-
tion of calcification both in vitro and in vivo by util-
izing these modalities.Conclusions
Vascular and valve calcification has been considered as
purely degenerative and unregulated processes until re-
cently. However, growing body of data indicates that
there are multiple causes of vascular and valve calcifica-
tion, including inflammatory, metabolic, genetic, and
epigenetic mechanisms, which cross-talk each other in acomplicated manner. Although it is important to prevent
vascular and valve calcification, it is also important to
optimize the therapeutic strategy according to the de-
fined characteristics of present calcification.
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